Additionally, addressing obesity through diet, exercise, and pharmacotherapy with anti-obesity drugs, such as glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide-GLP1 receptor agonists, may contribute to correcting hypokalemia. This evidence concerns the gene GIP and obesity disorder.